Lung Cancer

This book describes the molecular mechanisms of lung cancer development and progression that determine therapeutic interventions in the era of genomics, when the rapid evolution in lung cancer diagnosis and treatment necessitates critical review of new results to integrate advances into practice. The text opens with background and emerging information regarding the molecular biology of lung cancer pathogenesis. Updated results regarding lung cancer prevention and screening are discussed, followed by chapters on diagnostic techniques and pathological evaluation. This leads on to a detailed presentation of treatment modalities, from surgery and radiation therapy to standard chemotherapy and targeted agents. The coverage includes resistance to therapy and the emergence of immunotherapy for lung cancer; in addition, the current evidence in respect of small cell lung cancer is summarized. The book presents insights from experts across disciplines to emphasize the importance of collaborative care. Advances in our understanding of issues in geriatric oncology and palliative care complete the comprehensive discussion of lung cancer.

The best and most concise single source for state-of-the-artdiagnosis and treatment of lung cancer –newly revised,updated, and expanded. Lung cancer has long been the number-one cause of death from cancerevery year and the third most frequently diagnosed after breast andprostate cancers. In 2010, about 15% of all cancer diagnoses and30% of all cancer deaths were due to lung cancer. Needless to say,there is a great need for more rapid advancements in diagnosis andtreatment of this devastating disease. Here is the comprehensively revised, updated, and expandededition of the well-established, evidence-based reference book thatdeals with the most recent advances in lung cancer prevention,screening, diagnosis, research, and treatment for the clinician.Edited and authored by leading authorities in the field, thisFourth Edition of the highly regarded Lung Cancer is betterthan ever –featuring nine new chapters along with sevenre-formatted ones that are nearly brand new in content andapproach. It covers Smoking Prevention and Cessation; MolecularProfiling; Somatic Genome Alterations in Human Lung Cancers;Management of Multi-Focal Bronchioloalveolar Carcinoma (BAC);Primary Tracheal Tumors; Predictive Tumor Biomarkers for EGFRInhibitors; Non-Small Cell and Small-Cell Lung Carcinoma; andmore. This Fourth Edition of Lung Cancer: Provides the very latest research in the identification ofbiomarkers to predict a high risk for developing lung cancer– vital for implementing screening, diagnosis, and preventionstrategies Presents the newest lung cancer staging system, as well asupdated and cutting-edge surgical and radiation therapy techniquesthat make local tumor control more effective and less invasivewhile sparing normal tissues Discusses combined modality therapy and new chemotherapeuticagents which are yielding higher response rates and improvedsurvival when used in the adjuvant setting or concurrent withhighly sophisticated radiation or proton treatment Offers novel and emergent approaches to preventative,diagnostic, and therapeutic modalities with an emphasis on the bestevidence available from the latest studies and clinical trials With almost half of the revised and updated content being brandnew, Lung Cancer, Fourth Edition, is an important and vitalresource for all medical professionals and students involved in thecare and treatment of those struck with this catastrophicillness.

Rapid developments in the classification, screening and treatment of non-small-cell lung cancer (NSCLC) are improving outcomes for patients with the disease. This insightful guide is designed to bring you up to speed with recent advances, including: • the latest CT-based screening and interval growth imaging techniques • proposed changes to the TNM classification system • the increasing trend for minimally invasive and lung-sparing surgery • stereotactic radiation for early-stage tumors • new targeted therapies • breakthroughs in personalized medicine. Today's developments will change tomorrow's standards of care. 'Fast Facts: Non-Small-Cell Lung Cancer' is important reading for all health professionals and medical trainees working in this fast-moving area.

Lung cancer remains a major cause of cancer deaths throughout the world. It is an extremely lethal neoplasm: 80-90% of patients who develop lung cancer will die of their disease. The purpose of this book is to update cancer specialists, pulmonary physicians, thoracic surgeons and general practitioners about the many recent advances in the treatment, prevention and biology of lung cancer. Despite the overall poor prognosis for patients, a number of new chemotherapeutic drugs and regimens have been developed which result in a clinically meaningful improvement in survival for patients with nonsmall cell lung carcinoma. Four chapters in this book are devoted to reviewing these new drugs and drug combinations (paclitaxel, docetaxel, vinorelbine, gemcitabine, topoisomerase inhibitors). Advances in the management of locally advanced nonsmall cell and small cell lung cancer are considered, including combined-modality treatments using chemotherapy, surgery, and radiation therapy. Results of recent trials involving chemoprevention agents are also reported. Finally, the latest progress in understanding the molecular biology of this disease, and how it might impact on the clinical management of lung cancer patients, is discussed.

Carrying on the tradition established by its founding editor, the late Dr. Martin Abeloff, the 4th Edition of this respected reference synthesizes all of the latest oncology knowledge in one practical, clinically focused, easy-to-use volume. It incorporates basic science, pathology, diagnosis, management, outcomes, rehabilitation, and prevention – all in one convenient resource – equipping you to overcome your toughest clinical challenges. What's more, you can access the complete contents of this Expert Consult title online, and tap into its unparalleled guidance wherever and whenever you need it most! Equips you to select the most appropriate tests and imaging studies for diagnosing and staging each type of cancer, and manage your patients most effectively using all of the latest techniques and approaches. Explores all of the latest scientific discoveries' implications for cancer diagnosis and management. Employs a multidisciplinary approach - with contributions from pathologists, radiation oncologists, medical oncologists, and surgical oncologists - for well-rounded perspectives on the problems you face. Offers a user-friendly layout with a consistent chapter format • summary boxes • a full-color design • and more than 1,445 illustrations (1,200 in full color), to make reference easy and efficient. Offers access to the book's complete contents online – fully searchable – from anyplace with an Internet connection. Presents discussions on cutting-edge new topics including nanotechnology, functional imaging, signal transduction inhibitors, hormone modulators, complications of transplantation, and much more. Includes an expanded color art program that highlights key points, illustrates relevant science and clinical problems, and enhances your understanding of complex concepts.

Among the deadliest type of cancers, lung cancer faces several challenges in diagnosis and treatment: late diagnosis and misdiagnosis, inadequate tumor sampling, and resistance development to current therapies, among others. Together with advances in the understanding of molecular features, factors, and mechanisms involved in initiation and tumor progression, important improvements have occurred in diagnostics and therapeutics in the shape of advances in molecular genotyping, procedures for sampling, new potential, and less invasive sources of samples for the diagnosis and development of new targeted therapies. The aim of this book is to provide an exciting read on strategies in the diagnosis and therapy of lung cancer.

Textbook of Lung Cancer, 2nd edition, published in association with the European Society of Medical Oncology, is a comprehensive and multidisciplinary text, which examines all aspects of this disease, with contributions from a multinational team of authors on etiology, epidemiology, molecular biology, pathology, smoking, detection and management, clinical features, staging and prognostic factors, surgery, radiotherapy and chemotherapy. It provides essential information and guidance for specialist trainees in oncology, and for the many physicians and specialists involved in the field of lung cancer.

What is my prognosis? What are my treatment options? Which therapies would be the most effective for my stage of lung cancer? These and other frequently asked questions are addressed in this crucial reference designed to help patients educate themselves and obtain the best possible treatments. The completely revised second edition has been updated to include a discussion of the movement towards customized chemotherapy; treatment options for early-stage lung cancer including minimally invasive surgery; and the most promising treatments, among them multimodality therapy—a combination of surgery, chemotherapy, and radiation. Dr. Scott also surveys tests for early detection of lung cancer, talks about the importance of cancer staging, examines alternative treatments, and offers advice on coping with emotions such as "smoker's guilt."

Advances in CT have enabled us to detect small lung cancers, which has changed the lung cancer surgery from lobectomy to a lesser lobar resection such as a segmentectomy or wedge resection. While wedge resection is a simple procedure, it has a higher risk of local recurrence of cancer than a lobectomy. On the other hand, segmentectomy is a well known curative surgery for small lung cancers. However, it is difficult to perform accurately because of its anatomical complexity, which makes surgeons hesitant to use it. The book “Illustrated Anatomical Segmentectomy for Lung Cancer” provides readers a detailed explanation of segmentectomy with numerous easy-to-understand color illustrations showing the precise segmental anatomies for each pattern of the procedure. To better illustrate an accurate anatomical segmentectomy, the text shows details of anatomy during segmentectomy. This can involve up to 25 patterns, each of which is shown in roughly 10 illustrations.

Under the auspices of the 12th International Symposium on Special Aspects in Radiotherapy 2008 in Berlin, acknowledged experts presented their perspectives on small and non-small cell lung cancer, reflecting the latest standards and engaging in controversies in the diagnosis and treatment of this disease.In the first part of this volume, aspects of the diagnostic workup are highlighted from the histopathologist's point of view, followed by presentations concerning the value of PET-CT and whole-body MRI in the staging of lung cancer. The use and current methods in bronchoscopy, endoscopic ultrasound, video-endoscopy and mediastinoscopy are discussed in detail. The second section presents surgical and radio-oncological treatment concepts for stage I/II non-small cell lung cancer including stereotactic radiotherapy. The third section outlines the curative options for stage III NSCLC: extended surgical approaches , definitive radiochemotherapy and current concepts in adjuvant therapies. Emphasis is also placed on altered fractionation schemes in radiotherapy. Section 4 is dedicated to palliative procedures and the last section gives an in-depth presentation of small cell lung cancer.This book provides an excellent overview of up-to-date standards and future strategies in lung cancer treatment. It will be of great value to surgeons, radiation oncologists, pulmonary specialists and other clinicians interested in this disease.

Get a quick, expert overview of the many key facets of lung cancer evaluation and management with this concise, practical resource by Drs. Lynn T. Tanoue and Frank Detterbeck. This easy-to-read reference presents a summary of today’s best evidence-based approaches to diagnosis and management in this critical area. Covers diagnosis and evaluation, treatment considerations, and comprehensive care options for patients with lung cancer. Provides insight on evidence for today’s best practices, as well as future directions in the field. Consolidates today’s evidence-based information on the clinical aspects of lung cancer into one convenient resource.

This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.

Global experts, in conjunction with the International Association for the Study of Lung Cancer, bring you up to date with today’s best approaches to lung cancer diagnosis, treatment, and follow-up. IASLC Thoracic Oncology, 2nd Edition, keeps you abreast of the entire scope of this fast-changing field, from epidemiology to diagnosis to treatment to advocacy. Written in a straightforward, practical style for the busy clinician, this comprehensive, multidisciplinary title is a must-have for anyone involved in the care of patients with lung cancer and other thoracic malignancies. Offers practical, relevant coverage of basic science, epidemiology, pulmonology, medical and radiation oncology, surgery, pathology, palliative care, nursing, and advocacy. Provides authoritative guidance from the IASLC – the only global organization dedicated to the study of lung cancer. Includes new content on molecular testing, immunotherapy, early detection, staging and the IASLC staging system, surgical resection for stage I and stage II lung cancer, and stem cells in lung cancer. Features a new full-color design throughout, as well as updated diagnostic algorithms.

Nanotechnology-based Targeted Drug Delivery Systems for Lung Cancer is an indispensable resource that will help pharmaceutical scientists and clinical researchers design and develop novel drug delivery systems and devices for the treatment of lung cancer. As recent breakthroughs in nanomedicine are now making it possible to deliver drugs, genes and therapeutic agents to localized areas of disease to maximize clinical benefit, while also limiting unwanted side effects, this book explores promising approaches for the diagnosis and treatment of lung cancer using cutting-edge nanomedical technologies. Topics discussed include polymeric nanoparticles, solid lipid nanoparticles, liposomes, dendrimers, micelles and nanoemulsions. Provides an overview of an array of nanotechnology-based drug delivery systems Examines the design, synthesis and application of different nanocarriers in drug and gene delivery Provides an in-depth understanding of the design of targeted nanotherapeutics and technologies and its implication in various site-specific cancers

This is the second, completely updated edition of a comprehensive book in which many of the world’s leading lung cancer specialists discuss the recent advances in the radiation oncology of lung cancer and reflect on the latest research findings. The first three sections cover the basic science of lung cancer, clinical investigations, including histology and staging, and a wide range of fundamental treatment considerations. Current treatment strategies for small cell and non-small cell lung cancer are then explained and evaluated in detail, with due attention to novel approaches that promise further improvements in outcome. The various types of treatment-related toxicity are discussed, and quality of life studies and prognostic factors are also considered. After evaluating the latest technological and biological advances, including IMRT, IMAT, cyber knife treatment, and tomotherapy, the book concludes by thorough consideration of specific aspects of clinical research in lung cancer.

Ovine pulmonary adenocarcinoma (OPA) is a contagious lung cancer of sheep, first reported in South Africa in 1832 as "jaagsiekte" (chasing sickness). Starting in the 1970s evidence began to accumulate that the etiologic agent of OPA is a retrovirus, culminating in the deduction of the sequence of a novel retrovirus associated with the disease, jaagsiekte sheep retrovirus (JSRV). Very recently, substantial progress has been made in JSRV research, including isolation of infectious and oncogenic molecular clones of JSRV, identification and cloning of the JSRV receptor, and demonstration that the envelope gene of JSRV functions as an oncogene. This book is a consensus volume that comprehensively reviews all aspects of JSRV research, including natural history of the disease, histopathology of OPA, molecular biology of JSRV, oncogenic transformation by JSRV, and comparison with human lung cancer.

Tumors and Tumor-like Conditions of the Lung and Pleura is a superb visual resource that brings the state-of-the-art in thoracic diagnosis straight to the lab bench. Cesar A. Moran and Saul Suster are internationally recognized experts in pulmonary pathology who present a coherent and consistent approach to interpretation and diagnosis. Through more than 900 stunning photographs and a consistent, user-friendly format, this resource provides quality guidance on the diagnostic problems you face in everyday practice. You’ll get a host of innovative, practice-oriented features unavailable in any other text that streamline and facilitate diagnostic decision-making. Written by practitioners for practitioners, this visual resource is designed for quick and easy use. You can’t afford to be without it. Features over 900 high-quality full-color illustrations so you can recognize and diagnose any tissue sample under the microscope. Presents immunohistochemical and genetic features wherever relevant for comprehensive information on all of the investigative contexts important to formulating an accurate diagnosis. Includes summary tables throughout the text to simplify and clarify complex discussions and enable "at a glance" comparisons between entities. Provides practical advice from experts on pitfalls in differential diagnosis to help you avoid diagnostic errors.

Lung cancer is the leading cause of cancer death in the United States, but IGRT (image guided radiation therapy) offers the possibility of more aggressive and enhanced treatments. The only available source on the subject that emphasizes new imaging techniques, and provides step-by-step treatment guidelines for lung cancer, this source helps clinici

This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.

Lung cancer is one of the most common cancers in both men and women worldwide. Early diagnosis of lung cancer can significantly increase the chances of a patient's survival, yet early detection has historically been difficult. As a result, there has been a great deal of progress in the development of accurate and fast diagnostic tools in recent years. Lung Cancer and Imaging provides an introduction to both the methods currently used in lung cancer diagnosis and the promising new techniques that are emerging. Areas covered include the major trends and challenges in lung cancer detection and diagnosis, classification of cancer types, lung feature extraction in joint PET/CT images, and algorithms in the area of low dosage CT lung cancer images.